Skip to Main Content

Advertisement

Skip Nav Destination

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement